<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679601</url>
  </required_header>
  <id_info>
    <org_study_id>AN2690-ONYC-205</org_study_id>
    <secondary_id>C3371014</secondary_id>
    <nct_id>NCT00679601</nct_id>
  </id_info>
  <brief_title>Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)</brief_title>
  <official_title>An Open-label, Multiple-dose Study Of The Absorption And Systemic Pharmacokinetics Of An2690 Applied As A 7.5% Solution To All Toenails Of Adult Patients With Moderate To Severe Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the absorption and systemic pharmacokinetics of&#xD;
      AN2690 following daily application to all ten (10) toenails for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, open-label, multiple-dose study design will be used. Planned enrollment is&#xD;
      20 subjects to complete 15. Subjects must have a clinical diagnosis of onychomycosis of each&#xD;
      great toenail and a clinical diagnosis of onychomycosis of six of the remaining toenails.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2007</start_date>
  <completion_date type="Actual">May 31, 2007</completion_date>
  <primary_completion_date type="Actual">May 31, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of AN2690 in plasma and the concentration of AN2690 in urine over time</measure>
    <time_frame>Days 0, 1, 14, 15, and 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy measures of linear toenail growth, fungal culture results, KOH results, and clear toenail growth</measure>
    <time_frame>Days 0, 14, 28, and 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerance assessed by application site reactions, adverse events, vital signs, physical examinations, and 12-lead EKG</measure>
    <time_frame>Days 0-28, and 42</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Onychomycosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN2690</intervention_name>
    <description>AN2690 7.5% Solution, once daily for 28 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥18 and ≤65&#xD;
&#xD;
          -  BMI between 18.5 and 35 inclusive&#xD;
&#xD;
          -  Moderate to severe onychomycosis involving ≥80% of both great toenails, as determined&#xD;
             by visual inspection after the nail has been trimmed&#xD;
&#xD;
          -  Combined thickness of the nail plate and nail bed of each great toenail is &gt;3mm&#xD;
&#xD;
          -  At least 6 additional toenails with a clinical diagnosis of onychomycosis&#xD;
&#xD;
          -  If a female of childbearing potential, must be using of a highly effective method of&#xD;
             birth control or abstinence and be willing to remain on that same method of birth&#xD;
             control throughout the study&#xD;
&#xD;
          -  Capable of understanding and signing the informed consent, and willing to comply with&#xD;
             all requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to any of the study drug or any components in the test product(s)&#xD;
             or history of hypersensitivity or allergic reactions to any of the study preparations&#xD;
             as described in the Investigator's Brochure&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities that would interfere with the conduct&#xD;
             or interpretation of the study or jeopardize his/her safety&#xD;
&#xD;
          -  Diabetes mellitus requiring treatment other than diet and exercise&#xD;
&#xD;
          -  Willing to refrain from the use of nail cosmetics such as clear and or colored nail&#xD;
             lacquers from the screening visit until the end of the study&#xD;
&#xD;
          -  Nursing, pregnant or planning to become pregnant during the study&#xD;
&#xD;
          -  Failure to complete the specified washout period(s) for the following topical:&#xD;
&#xD;
               1. Topical antifungal applied to the feet (does not include antifungals for&#xD;
                  treatment of T. pedis during the study): 4 weeks&#xD;
&#xD;
               2. Anti-inflammatories, corticosteroids, topical immunomodulators: 2 weeks&#xD;
&#xD;
          -  Failure to complete the specified washout period(s) for the following systemic&#xD;
             medications:&#xD;
&#xD;
               1. Corticosteroids (including intramuscular injections): 2 weeks&#xD;
&#xD;
               2. Antifungals for treatment of onychomycosis or any systemic antifungal with known&#xD;
                  activity against dermatophyte: 24 weeks&#xD;
&#xD;
               3. Systemic immunomodulators: 4 weeks&#xD;
&#xD;
          -  Received treatment of any type for cancer within the last 6 months&#xD;
&#xD;
          -  History of any significant internal disease&#xD;
&#xD;
          -  Nail or anatomic abnormalities of the toe, e.g., genetic nail disorders, primentary&#xD;
             disorders, onychogryphosis, trauma to the nail(s) to be treated&#xD;
&#xD;
          -  AIDS or AIDS related complex&#xD;
&#xD;
          -  History of street drug or alcohol abuse&#xD;
&#xD;
          -  Donated or lost blood, or participated in a clinical study which involved the&#xD;
             withdrawal of a large volume of blood (480 mL or more), during the six-week period&#xD;
             preceding study initiation&#xD;
&#xD;
          -  Donated plasma during the two week period preceding study initiation&#xD;
&#xD;
          -  Participated in any other trial of an investigational drug or device within 30 days&#xD;
             prior to enrollment or participation in a research study concurrent with this study&#xD;
&#xD;
          -  Prior enrollment in a study using the study drug, AN2690&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>J&amp;S Studies</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>Fungal Nail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tavaborole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

